Novartis International AG Novartis investigational BYL719 alpelisib plus fulvestrant consistently improved PFS in patients with PIK3CA mutated HRHER2 advanced breast cancer in new SOLAR1 analyses

Novartis International AG: Novartis investigational BYL719 (alpelisib) plus fulvestrant consistently improved PFS in patients with PIK3CA mutated HR+/HER2- advanced breast cancer in new SOLAR-1 analyses

10:42 EST 6 Dec 2018 | FinanzNachrichten

Novartis International AG / Novartis investigational BYL719 (alpelisib) plus fulvestrant consistently improved PFS in patients with PIK3CA mutated HR+/HER2- advanced breast cancer in new SOLAR-1 an...

More From BioPortfolio on "Novartis International AG: Novartis investigational BYL719 (alpelisib) plus fulvestrant consistently improved PFS in patients with PIK3CA mutated HR+/HER2- advanced breast cancer in new SOLAR-1 analyses"